NanoViricides Raises $2M for Broad-Spectrum Antiviral Development

NanoViricides, Inc. (NYSE American: NNVC) has announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering includes the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares at an exercise price of $1.75 per share, with a three-year term. Closing is anticipated on or about May 18, 2026, subject to customary conditions. This move aims to strengthen the company's financial position as it advances its clinical-stage antiviral drug candidate.

NanoViricides is a clinical-stage company pioneering broad-spectrum antivirals using host-mimetic nanomedicine technology. Its lead drug, NV-387, has received Orphan Drug Designation from the FDA, offering potential market exclusivity and other benefits. NV-387 is designed to be a revolutionary antiviral for respiratory viral illnesses and has shown efficacy in animal models against Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles. The company's focus on broad-spectrum antivirals is crucial in an era where viral variants pose ongoing challenges.

MissionIR, a communications platform within the Dynamic Brand Portfolio @ IBN, is facilitating the dissemination of this news. MissionIR specializes in syndicated content to enhance visibility for companies in the investment community, leveraging a network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. This partnership ensures that NanoViricides' updates reach a wide audience of investors and stakeholders. For more details, the full press release is available at https://ibn.fm/Z8Etj.